ACUTAAS · Basic Materials · Specialty Chemicals
Composite scorecard: 62/100 — Quality 79 · Valuation 15 · Momentum 100
| Share price | ₹3,656.20 |
| Market cap | ₹27,843 Cr |
| P/E ratio | 99.0 |
| P/B ratio | 16.8 |
| ROE | 32.1% |
| ROCE | 16.5% |
| Dividend yield | 0.04% |
| Book value | ₹201.93 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,339 Cr | ₹356 Cr | 36.0% |
| 2025 | ₹1,007 Cr | ₹160 Cr | 23.0% |
| 2024 | ₹717 Cr | ₹49 Cr | 18.0% |
| 2023 | ₹617 Cr | ₹83 Cr | 20.0% |
| 2022 | ₹520 Cr | ₹72 Cr | 20.0% |
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrol